MARKET

IRD

IRD

Opus Genetics
NASDAQ
1.130
+0.010
+0.89%
After Hours: 1.129 -0.001 -0.10% 19:59 07/11 EDT
OPEN
1.110
PREV CLOSE
1.120
HIGH
1.130
LOW
1.080
VOLUME
190.88K
TURNOVER
--
52 WEEK HIGH
2.180
52 WEEK LOW
0.6500
MARKET CAP
67.42M
P/E (TTM)
-0.5685
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IRD last week (0630-0704)?
Weekly Report · 6d ago
OPUS GENETICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/03 20:30
Weekly Report: what happened at IRD last week (0623-0627)?
Weekly Report · 06/30 09:56
Opus Genetics: Strategic Collaborations and Promising Trial Outcomes Justify Buy Rating
TipRanks · 06/27 10:15
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Benzinga · 06/26 17:07
Opus Genetics: Promising Developments and Strong Pipeline Justify Buy Rating
TipRanks · 06/26 13:55
Craig-Hallum Reaffirms Their Buy Rating on Opus Genetics (IRD)
TipRanks · 06/26 12:36
Opus Genetics Announces Positive Phase 3 Trial Results
TipRanks · 06/26 11:29
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.